Average Weight Loss in Clinical Trials
Patients on Wegovy (semaglutide) lost 15-20% of their body weight over 68 weeks in key trials like STEP 1. For someone starting at 230 pounds, that's about 35-45 pounds on average.[1][2] Results vary by adherence, diet, and exercise.
How Long to See Results
Weight loss starts within 4-12 weeks, with most gains by 68 weeks. Weekly 2.4 mg doses ramp up gradually to minimize side effects. Early dropouts see less, around 5-10%.[1][3]
Factors Affecting Your Results
Higher starting BMI (over 30) predicts better loss, up to 22%. Men often lose more absolute pounds; women more percentage-wise. Combining with calorie cuts and activity boosts outcomes by 5-10% extra. Age over 65 or diabetes cuts averages to 10-12%.[2][4]
Realistic Expectations vs. Hype
Not everyone hits 20%; 1 in 5 lose under 10%. Plateaus happen after 1 year; maintenance requires lifelong use or tapering. Social media claims of 50+ pounds fast are outliers or edited.[3][5]
Who Gets the Best Results
Best for BMI 30+ or 27+ with conditions like hypertension. Responders (top 25%) lose 25%+; non-responders under 5% quit early. Genetics and gut microbiome influence response.[4][6]
Side Effects Impacting Weight Loss
Nausea (44%), diarrhea (30%), and vomiting slow some patients, causing 10-20% dropout. These fade after 20 weeks but can limit intake initially.[1][2]
Staying Off the Weight Long-Term
Two-thirds regain most weight within a year of stopping. Pairing with behavior therapy or switching to lower-dose keeps 10% off at 2 years.[5][7]
Cost and Access Realities
$1,300/month without insurance; generics or compounded versions run $200-500 but risk quality issues. Patents hold until 2032 in the US, delaying cheap copies.[8][9]
[1] NEJM: Semaglutide 2.4 mg for Weight Loss (STEP 1 Trial), https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
[2] Novo Nordisk STEP Program Data, https://www.novomedlink.com/obesity/products/treatments/wegovy/efficacy-safety/weight-loss.html
[3] JAMA: Long-Term Weight Loss with Semaglutide, https://jamanetwork.com/journals/jama/fullarticle/2790281
[4] Lancet: Predictors of Response to Semaglutide, https://www.thelancet.com/journals/landia/article/PIIS2213-8587(21)00032-5/fulltext
[5] Nature Medicine: Weight Regain After Semaglutide, https://www.nature.com/articles/s41591-023-02526-w
[6] DrugPatentWatch: Wegovy Patent Expiry, https://www.drugpatentwatch.com/p/tradename/WEGOVY
[7] Obesity Journal: Maintenance Strategies Post-GLP1, https://onlinelibrary.wiley.com/doi/10.1002/oby.24000
[8] Novo Nordisk Investor: Wegovy Pricing, https://www.novonordisk.com/content/dam/nncorp/global/en/investors/irmaterial/annualreport/2023/AR2023.pdf
[9] FDA Label: Wegovy Prescribing Info, https://www.accessdata.fda.gov/drugsatfdadocs/label/2023/215256s007lbl.pdf